Who owns Avalo Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of AVTX from SEC Form 13F filings across 148 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 148 institutions disclosed 71.6M shares of Avalo Therapeutics, Inc. worth $1.10B — about 130.1% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
148
13F holders
$1.10B
value, 2026 filers
130.1%
of shares outstanding (71.6M sh)
38
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of AVTX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 5.3M | $80.5M | 0.0% | 9.5% | +2.9% |
| 2 | BlackRock, Inc. | 5.0M | $76.0M | 0.0% | 9% | +13.6% |
| 3 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 4.0M | $60.9M | 0.3% | 7.2% | +59.1% |
| 4 | Deep Track Capital, LP | 3.6M | $55.3M | 0.9% | 6.6% | 0.0% |
| 5 | Caligan Partners LP | 3.3M | $50.1M | 3.1% | 5.9% | +3.3% |
| 6 | Affinity Asset Advisors, LLC | 3.2M | $49.7M | 2.0% | 5.9% | +11.9% |
| 7 | TCG Crossover Management, LLC | 3.0M | $46.3M | 1.3% | 5.5% | 0.0% |
| 8 | STATE STREET CORP | 2.6M | $39.3M | 0.0% | 4.7% | -11.3% |
| 9 | Avoro Capital Advisors LLC | 2.4M | $36.5M | 0.4% | 4.3% | +1.9% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | $34.6M | 0.0% | 4.1% | -0.4% |
| 11 | Nantahala Capital Management, LLC | 2.1M | $32.8M | 1.0% | 3.9% | +15.0% |
| 12 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.9M | $29.4M | 0.0% | 3.5% | +46.2% |
| 13 | BANK OF AMERICA CORP /DE/ | 1.8M | $27.2M | 0.0% | 3.2% | -7.2% |
| 14 | Point72 Asset Management, L.P. | 1.6M | $24.9M | 0.0% | 3% | -31.9% |
| 15 | BRAIDWELL LP | 1.6M | $24.7M | 1.0% | 2.9% | -1.2% |
| 16 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.6M | $24.5M | 0.0% | 2.9% | -7.5% |
| 17 | Trails Edge Capital Partners, LP | 1.5M | $23.0M | 3.3% | 2.7% | +68.2% |
| 18 | ALLIANCEBERNSTEIN L.P. | 1.4M | $21.4M | 0.0% | 2.5% | +10.8% |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $19.4M | 0.0% | 2.3% | +14.3% |
| 20 | AMERIPRISE FINANCIAL INC | 1.1M | $16.5M | 0.0% | 2% | +21.1% |
| 21 | Commodore Capital LP | 1.0M | $15.6M | 1.2% | 1.8% | 0.0% |
| 22 | RA CAPITAL MANAGEMENT, L.P. | 1.0M | $15.3M | 0.2% | 1.8% | 0.0% |
| 23 | Parkman Healthcare Partners LLC | 929,432 | $14.2M | 1.3% | 1.7% | +21.3% |
| 24 | BVF INC/IL | 907,406 | $13.9M | 0.5% | 1.6% | -56.3% |
| 25 | Vestal Point Capital, LP | 800,000 | $12.3M | 0.3% | 1.5% | +3.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.